<DOC>
	<DOC>NCT01069796</DOC>
	<brief_summary>Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).</brief_summary>
	<brief_title>Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Female histologically confirmed adenocarcinoma of the breast ER, PR, HER2 disease Measurable disease Patients may received prior radiotherapy as adjuvant treatment or/and metastatic disease provided that they have progressive disease at study entry Prior chemotherapy for metastatic disease HER2 positive and/or hormonal receptor positive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>triple negative</keyword>
	<keyword>metastatic</keyword>
	<keyword>breast cancer</keyword>
	<keyword>First line chemotherapy</keyword>
</DOC>